Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Diluted Average) (2016 - 2025)

Mimedx's Shares Outstanding (Diluted Average) history spans 14 years, with the latest figure at $149.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.45% year-over-year to $149.7 million; the TTM value through Dec 2025 reached $149.7 million, changed 0.45%, while the annual FY2025 figure was $149.7 million, 0.45% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $149.7 million at Mimedx, roughly flat from $149.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $150.0 million in Q1 2024 and bottomed at $109.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $116.4 million (2023), against an average of $128.9 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) skyrocketed 31.14% in 2024 before it fell 0.23% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $110.4 million in 2021, then increased by 2.32% to $112.9 million in 2022, then grew by 29.27% to $146.0 million in 2023, then rose by 2.11% to $149.0 million in 2024, then rose by 0.45% to $149.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Shares Outstanding (Diluted Average) are $149.7 million (Q4 2025), $149.7 million (Q3 2025), and $149.5 million (Q2 2025).